Human CYP2B6: expression, inducibility and catalytic activities.
about
Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 proteinStructural and Thermodynamic Basis of (+)-α-Pinene Binding to Human Cytochrome P450 2B6Insights into CYP2B6-mediated drug-drug interactionsThe chemopotentiation of cisplatin by the novel bioreductive drug AQ4NSmoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium.Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeDrug-metabolizing cytochrome P450s in the brain.Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetyleneHuman hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon.Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancerGeneration and characterization of a CYP2A13/2B6/2F1-transgenic mouse modelDose of Phenobarbital and Age of Treatment at Early Life are Two Key Factors for the Persistent Induction of Cytochrome P450 Enzymes in Adult Mouse LiverGene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.Bioactivation of chlorpyrifos by CYP2B6 variants.Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevancePilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis.The role of african american ethnicity and metabolism in sentinel polychlorinated biphenyl congener serum levelsThe effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavirSelective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration.Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study.Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6.High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates.Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz.Identification of non-reported bupropion metabolites in human plasma.Systematic and simultaneous gene profiling of 84 drug-metabolizing genes in primary human hepatocytes.
P2860
Q24671717-D1F3D9EF-0815-4857-9F8C-694EBC0ED48DQ27678713-345316E5-D86E-48D5-9187-3066E65A49C4Q28078857-982035FF-7E2A-4D22-8E96-B138FFE332E0Q28346061-8615CCB3-F2F1-4C17-83C0-2B754D3FAC0AQ33339025-7E53DA64-77A7-42DB-B250-49C093876A4FQ33646358-D7EE8E7D-3F70-4E24-A225-06F254DCBA7BQ34169785-2E8C3189-F9F2-4AD2-92DB-F06C9B07C967Q34325249-68E6A8FE-9C52-4201-B0AA-9BA54ADC2C49Q34824471-1A1553DC-8C5A-4363-9415-FBFB8FD69502Q35030396-F243BE34-E6DE-4112-B416-38D092EF31F0Q35579527-263BB1E6-E821-4FD9-918C-7AFE7BF69167Q35647132-F34E6833-40FB-4A88-A78D-9283164A1381Q35677725-09467427-7615-444F-99A1-C17A0E7BA901Q35996452-E088DDF2-6584-492E-89D4-1816952B5968Q36316485-3D62E512-7A7A-4229-98BD-506792F34500Q36320257-AF61E431-0AF4-4FE1-A95A-A0E570D33357Q36406259-BCB5294F-13A3-4290-AE87-3BBE29E68BCFQ36462008-27768AF3-FB63-4DFC-B649-76883993960EQ36593723-7B915563-DE29-4E93-8684-2C45E792A2B6Q36618692-456CF50C-80FC-4C22-B9AE-38BD6F97CD4CQ36657589-EEAE7574-E07D-4DA5-A85F-2CDF9CB8A176Q36820603-9F2A4A00-F760-4421-AE2E-D5169BA1FB28Q37089317-7507620C-DDDB-488D-B8D5-A77B26BCA713Q37193089-C842829F-267E-499E-8DB8-D383888B815FQ37386629-8E19106F-F1C8-4795-BAA8-B4833B6F39C3Q38882614-D06DC810-0C48-4438-8D06-842D39C4CAC5Q40443135-613734E2-BC42-45B8-B5B2-3032369CD2ACQ41054488-3B9162D3-C4FC-4F91-8AE8-0FE016F53EB8Q41153557-E941D19F-C292-4AD9-9DC3-A7C9BCBFEC90Q41875935-A8553A83-E1A3-4C9B-A8FC-934DC2F3389AQ41934777-08A68A35-2AD9-40FA-9CCB-343DA4E8D342Q41987336-C985E50C-550E-41F4-8FEB-891F9314EC7AQ42260918-3E3C40CD-EDEF-45B0-BD83-9FD867E7FEF6Q42360559-734CB10A-614F-4597-A8EC-0DF41291F972Q46757516-211F6240-B0A4-46F4-B434-83BE2AD7937B
P2860
Human CYP2B6: expression, inducibility and catalytic activities.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Human CYP2B6: expression, inducibility and catalytic activities.
@en
type
label
Human CYP2B6: expression, inducibility and catalytic activities.
@en
prefLabel
Human CYP2B6: expression, inducibility and catalytic activities.
@en
P2093
P1476
Human CYP2B6: expression, inducibility and catalytic activities.
@en
P2093
F Bohnenstengel
I de Waziers
J C Gautier
V de Berardinis
P304
P577
1999-06-01T00:00:00Z